WNK2 and cancer: c-MET is often aberrantly activated in cancer, leading to the persistent activation of several downstream signaling pathways, including the mitogen-activated protein kinase (MAPK) and phosphatidylinositol 3-kinase (PI3K)-AKT pathways [29].